FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886801809> ?p ?o ?g. }

• W2886801809 endingPage "1270" @default.
• W2886801809 startingPage "1263" @default.
• W2886801809 abstract "Zoledronic acid (ZA) is the most widely used bisphos­phonate to treat cancer-induced bone disease. There is evidence that bisphosphonates have direct antitumor activity and that their combination with anticancer agents can significantly enhance the effect of treatment. We evaluated whether the combination of ZA with different platinum compounds exerts a synergistic effect in breast cancer cell lines and we investigated the mechanisms of action involved. This study was performed on four breast cancer cell lines, MCF-7, SKBR3, MDA-MB-231 and BRC-230, and confirmed on a primary culture obtained from a breast cancer bone metastasis specimen. ZA (50 µM) was administered for 72 h alone or in combination with cisplatin (Cis) or carboplatin. Drug-induced growth inhibition was detected by sulforhodamine B assay, apoptosis and cell cycle regulation were detected by flow cytometry, and protein expression was evaluated by western blot analysis. MCF-7 and SKBR3 showed very low sensitivity to the three drugs tested. The ZA + Cis combination exerted a high antitumor activity in the two triple-negative lines MDA-MB-231 and BRC-230. An important synergistic effect was obtained in MDA-MB-231 and an additive effect was observed in BRC-230. The p21, pMAPK and m-TOR pathways were regulated by this combined treatment, particularly at lower Cis doses. Carboplatin did not show antitumor activity either alone or in combination with ZA. In conclusion, the potential novel treatment schedule identified for triple-negative breast cancer could prove beneficial in view of the limited therapeutic options available for patients and also since the synergism with ZA would enable lower Cis doses to be used, thus reducing toxicity. Although further research in a clinical setting is warranted, our results on cell lines has been confirmed on a human primary bone metastasis culture." @default.
• W2886801809 created "2018-08-22" @default.
• W2886801809 creator A5002947460 @default.
• W2886801809 creator A5015241599 @default.
• W2886801809 creator A5016193335 @default.
• W2886801809 creator A5035580064 @default.
• W2886801809 creator A5047952050 @default.
• W2886801809 creator A5050243008 @default.
• W2886801809 creator A5070016179 @default.
• W2886801809 creator A5075055655 @default.
• W2886801809 date "2013-02-06" @default.
• W2886801809 modified "2023-10-14" @default.
• W2886801809 title "Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines" @default.
• W2886801809 cites W1873492158 @default.
• W2886801809 cites W1967479801 @default.
• W2886801809 cites W1975805439 @default.
• W2886801809 cites W1984431867 @default.
• W2886801809 cites W1986630057 @default.
• W2886801809 cites W1987822201 @default.
• W2886801809 cites W1989014251 @default.
• W2886801809 cites W2007001439 @default.
• W2886801809 cites W2021852492 @default.
• W2886801809 cites W2024981400 @default.
• W2886801809 cites W2029353393 @default.
• W2886801809 cites W2031762038 @default.
• W2886801809 cites W2033294313 @default.
• W2886801809 cites W2041868422 @default.
• W2886801809 cites W2045369683 @default.
• W2886801809 cites W2054351138 @default.
• W2886801809 cites W2063685408 @default.
• W2886801809 cites W2065674163 @default.
• W2886801809 cites W2068522538 @default.
• W2886801809 cites W2077073060 @default.
• W2886801809 cites W2077510597 @default.
• W2886801809 cites W2077546229 @default.
• W2886801809 cites W2079712521 @default.
• W2886801809 cites W2097286610 @default.
• W2886801809 cites W2098097319 @default.
• W2886801809 cites W2100244598 @default.
• W2886801809 cites W2106787323 @default.
• W2886801809 cites W2109689528 @default.
• W2886801809 cites W2121917721 @default.
• W2886801809 cites W2134539328 @default.
• W2886801809 cites W2135945275 @default.
• W2886801809 cites W2136983579 @default.
• W2886801809 cites W2140503098 @default.
• W2886801809 cites W2144860907 @default.
• W2886801809 cites W2144957471 @default.
• W2886801809 cites W2151802968 @default.
• W2886801809 cites W2155208683 @default.
• W2886801809 cites W2171178563 @default.
• W2886801809 cites W2172234791 @default.
• W2886801809 cites W2615372951 @default.
• W2886801809 cites W4242024627 @default.
• W2886801809 doi "https://doi.org/10.3892/ijo.2013.1809" @default.
• W2886801809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23403907" @default.
• W2886801809 hasPublicationYear "2013" @default.
• W2886801809 type Work @default.
• W2886801809 sameAs 2886801809 @default.
• W2886801809 citedByCount "19" @default.
• W2886801809 countsByYear W28868018092014 @default.
• W2886801809 countsByYear W28868018092015 @default.
• W2886801809 countsByYear W28868018092016 @default.
• W2886801809 countsByYear W28868018092018 @default.
• W2886801809 countsByYear W28868018092019 @default.
• W2886801809 countsByYear W28868018092020 @default.
• W2886801809 countsByYear W28868018092021 @default.
• W2886801809 countsByYear W28868018092022 @default.
• W2886801809 countsByYear W28868018092023 @default.
• W2886801809 crossrefType "journal-article" @default.
• W2886801809 hasAuthorship W2886801809A5002947460 @default.
• W2886801809 hasAuthorship W2886801809A5015241599 @default.
• W2886801809 hasAuthorship W2886801809A5016193335 @default.
• W2886801809 hasAuthorship W2886801809A5035580064 @default.
• W2886801809 hasAuthorship W2886801809A5047952050 @default.
• W2886801809 hasAuthorship W2886801809A5050243008 @default.
• W2886801809 hasAuthorship W2886801809A5070016179 @default.
• W2886801809 hasAuthorship W2886801809A5075055655 @default.
• W2886801809 hasBestOaLocation W28868018091 @default.
• W2886801809 hasConcept C121608353 @default.
• W2886801809 hasConcept C126322002 @default.
• W2886801809 hasConcept C185592680 @default.
• W2886801809 hasConcept C190283241 @default.
• W2886801809 hasConcept C191560914 @default.
• W2886801809 hasConcept C2776694085 @default.
• W2886801809 hasConcept C2778239845 @default.
• W2886801809 hasConcept C2780110267 @default.
• W2886801809 hasConcept C2781190966 @default.
• W2886801809 hasConcept C2781451048 @default.
• W2886801809 hasConcept C29537977 @default.
• W2886801809 hasConcept C2994423619 @default.
• W2886801809 hasConcept C502942594 @default.
• W2886801809 hasConcept C530470458 @default.
• W2886801809 hasConcept C55493867 @default.
• W2886801809 hasConcept C62112901 @default.
• W2886801809 hasConcept C71924100 @default.
• W2886801809 hasConcept C98274493 @default.
• W2886801809 hasConceptScore W2886801809C121608353 @default.

• next